Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
前收盤價
US$27.24
+US$0.28 · +1.04%
盤中時間採用ET。市場資料可能有所延遲。
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
日內區間
目前US$27.24
52週區間
目前US$27.24
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 61.64億 USD | 58.1億 USD | 55.49億 USD | 52.15億 USD | 52.12億 USD |
| 銷貨成本 | 19.57億 USD | 17.31億 USD | 16.54億 USD | 15.15億 USD | 15.14億 USD |
| 毛利 | 42.07億 USD | 40.79億 USD | 38.95億 USD | 37億 USD | 36.98億 USD |
| 研究與開發 | 3.46億 USD | 3.43億 USD | 3.39億 USD | 3.45億 USD | 3.56億 USD |
| 銷售、一般及管理費用 | 30.36億 USD | 29.04億 USD | 28.34億 USD | 27.07億 USD | 26.37億 USD |
| 營業費用 | 34.13億 USD | 34.22億 USD | 34.7億 USD | 32.5億 USD | 31.05億 USD |
| 利息收入 | 2806.54萬 USD | 2401.01萬 USD | 3413.18萬 USD | 1399.14萬 USD | 599.93萬 USD |
| 利息支出 | 1.41億 USD | 1.5億 USD | 1.33億 USD | 7995.06萬 USD | 7999.05萬 USD |
| 折舊和攤銷 | 5.73億 USD | 5.55億 USD | 5.27億 USD | 5.48億 USD | 5.63億 USD |
| 營業利益 | 7.94億 USD | 6.57億 USD | 4.25億 USD | 4.5億 USD | 5.93億 USD |
| 淨利 | 6.25億 USD | 4.12億 USD | 2.63億 USD | 2.23億 USD | 5.24億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$31.91
上漲空間 17.14%年度分割調整後的每股現金分配。
US$0.762
2025年(完整年度)+1.6% 自從 2021
2026年(部分年度):US$0.794
US$0.75
2,021
US$0.75
2,022
US$0.75
2,023
US$0.75
2,024
US$0.762
2,025
US$0.794
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年10月2日 | US$0.312Semi-Annual | 2026年10月2日 | 2026年11月6日 |
股息 | 2026年3月27日 | US$0.482Semi-Annual | 2026年3月27日 | 2026年5月27日 |
股息 | 2025年10月3日 | US$0.30Semi-Annual | 2025年10月3日 | 2025年11月7日 |
股息 | 2025年3月28日 | US$0.462Semi-Annual | 2025年3月28日 | 2025年5月28日 |
股息 | 2024年10月4日 | US$0.288Semi-Annual | 2024年10月4日 | 2024年11月8日 |
股息 | 2024年4月1日 | US$0.462Semi-Annual | 2024年4月2日 | 2024年5月22日 |
除息 2026年10月2日
US$0.312
Semi-Annual
2026年10月2日登記 · 支付日 2026年11月6日
除息 2026年3月27日
US$0.482
Semi-Annual
2026年3月27日登記 · 支付日 2026年5月27日
除息 2025年10月3日
US$0.30
Semi-Annual
2025年10月3日登記 · 支付日 2025年11月7日
除息 2025年3月28日
US$0.462
Semi-Annual
2025年3月28日登記 · 支付日 2025年5月28日
除息 2024年10月4日
US$0.288
Semi-Annual
2024年10月4日登記 · 支付日 2024年11月8日
除息 2024年4月1日
US$0.462
Semi-Annual
2024年4月2日登記 · 支付日 2024年5月22日
報告持有此股票曝險的交易所交易基金。
Vanguard Total International Stock ETFVXUS1071.02萬0.00%6657億 USD0.05%US$84.82+0.86%
Vanguard FTSE Emerging Markets ETFVWO1045.3萬0.01%1685億 USD0.06%US$59.76+1.12%
Dimensional - International Core Equity 2 ETFDFIC802.49萬0.05%150.17億 USD0.22%US$37.53+0.64%
Avantis International Equity ETFAVDE734.44萬0.04%192.24億 USD0.23%US$89.80+0.58%
Dimensional World ex U.S. Core Equity 2 ETFDFAX488.23萬0.04%123.36億 USD0.28%US$37.08+0.76%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP213.59萬0.08%26.06億 USD0.20%US$66.35+1.13%
Vanguard FTSE All-World ex-US ETFVEU171.93萬0.00%986億 USD0.04%US$82.82+0.78%
Vanguard International High Dividend Yield ETFVYMI85.89萬0.00%228億 USD0.07%US$100.66+0.60%
Vanguard Total International Stock ETFVXUS
Vanguard FTSE Emerging Markets ETFVWO
Dimensional - International Core Equity 2 ETFDFIC
Avantis International Equity ETFAVDE
Dimensional World ex U.S. Core Equity 2 ETFDFAX
State Street SPDR S&P Kensho New Economies Composite ETFKOMP
Vanguard FTSE All-World ex-US ETFVEU
Vanguard International High Dividend Yield ETFVYMIAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。